Compare FRT & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRT | LNTH |
|---|---|---|
| Founded | 1962 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 4.4B |
| IPO Year | N/A | 2015 |
| Metric | FRT | LNTH |
|---|---|---|
| Price | $102.10 | $65.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $109.93 | $77.67 |
| AVG Volume (30 Days) | 627.6K | ★ 1.1M |
| Earning Date | 10-31-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | ★ 3.95 | 2.39 |
| Revenue | $1,257,396,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $5.51 | $0.01 |
| Revenue Next Year | $5.27 | $1.24 |
| P/E Ratio | ★ $25.78 | $27.26 |
| Revenue Growth | ★ 6.11 | 1.95 |
| 52 Week Low | $80.65 | $47.25 |
| 52 Week High | $115.59 | $111.29 |
| Indicator | FRT | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 66.71 |
| Support Level | $100.00 | $60.15 |
| Resistance Level | $102.58 | $67.01 |
| Average True Range (ATR) | 1.45 | 2.15 |
| MACD | 0.52 | 0.41 |
| Stochastic Oscillator | 89.97 | 79.06 |
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 102 properties, which includes 27.4 million square feet of retail space and 3,000 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.